Ardelyx Inc. To Present At The 22nd Annual Future Leaders In The Biotech Industry Conference
FREMONT, Calif., March 13, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that Mike Raab, President and Chief Executive Officer, will present a corporate overview at the 22nd Annual Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015, at 9:30 a.m. Eastern Time. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York.
The presentation will be available through a live audio webcast accessible through a link in the Investor Relations section of Ardelyx's website at ir.ardelyx.com. A replay of the webcast will be available at this site for 30 days.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, the Company has discovered and designed tenapanor. Ardelyx formed a partnership with AstraZeneca in October 2012 to develop and commercialize tenapanor. The Company and AstraZeneca have completed two Phase 2b clinical trials evaluating tenapanor to treat patients with constipation-predominant irritable bowel syndrome (IBS-C), and to treat hyperphosphatemic patients with chronic kidney disease on dialysis (CKD-5D). In an ongoing Phase 2a clinical study in CKD patients, tenapanor is being evaluated for its effect on kidney function and fluid overload. In addition to tenapanor, the Company has discovered small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in CKD-5D, a program licensed to Sanofi, and independently is advancing several additional research programs focused in cardio-renal, gastrointestinal and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at www.ardelyx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-22nd-annual-future-leaders-in-the-biotech-industry-conference-300050128.html
SOURCE Ardelyx, Inc.